South Korea Approves Another COVID-19 Vaccine Study

South Korea-based EuBiologics announced the Korean Ministry of Food and Drug Safety approved a clinical trial of 'EuCOVAC-19', a new COVID-19 vaccine candidate. The clinical trial is aimed at evaluating EuCOVAC-19’s safety and immunogenicity for healthy adults and will proceed with Phase 1 and Phase 2 studies sequentially.

EuCOVAC-19 is a recombinant vaccine based on surface antigen proteins from the COVID-19 virus, SARS-CoV-2. The vaccine's surface antigen proteins form neutralizing antibodies by stimulating immune cells. When the COVID-19 coronavirus breaks into the body, the antibodies kill the COVID-19 virus.

The Korean ministry stated that it had given clinical trial approval to seven COVID-19 vaccines, including EuCOVAC-19, and fifteen COVID-19 treatments, as of January 11, 2021.

During the COVID-19 pandemic, 1,316 fatalities have been reported by South Korea's population of 51 million.